AMDL Increases Pipeline
by Richard Daverman, PhD
ChinaBio Today
AMDL Inc. (ADL) announced its wholly-owned China subsidiary, Jade Pharmaceutical, will increase its product pipeline by increasing in-house research and in-licensing products from other companies.
Currently, Jade has two products under consideration by the SFDA, AMDL’s DR-70(R) cancer diagnostic test kit and docetaxel injectables. AMDL expects that both products will be approved by the SFDA and launched by mid-2008. AMDL anticipates that the docetaxel product will become its best selling product, eventually attaining revenues of $10 million per year.
AMDL has made several attempts to win approval in the US for its DR-70(R) cancer diagnostic test kit, using the equivalency criterion as a means to attain the FDA’s blessing. But each time, the FDA has ruled that the test does not meet the equivalency criterion. AMDL claims that the DR-70® kit, a blood test, has been shown to detect up to 13 different common cancers, including lung (small and non-small cell), stomach, breast, rectal, colon and liver cancer. AMDL has been selling the kit in Asia.
Jade has four other products in development: EO-H, an herbal treatment to improve bone density; TouJin NiangShi, an herbal liver cancer treatment; and Drotaverrine Hydrochloric and Diammonium Glycyrrhizinate, both of which are chemotherapy therapeutic products. These four products are scheduled to complete the SFDA review process in the next two to three years.
Jade Pharmaceuticals already manufactures large volume injectable fluids, tablets and other products, holding licenses for 133 products. It also manufactures 107 generic, over-the-counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
AMDL completed its acquisition of Jade in September 2006. It paid 2.743 million shares of AMDL stock for the assets of Jade Pharmaceutical, which included Jade’s two operating subsidiaries.
In August, AMDL announced Q2 revenues of $2.264 million, a 69% jump over the first quarter numbers. Gross profits were $1.15 million, but a non-cash charge of $2.264 million took the company into a substantial loss. AMDL said the charge was for depreciation, common stock, warrants and options that were issued.
AMDL is headquartered in Tustin, CA. Jade Pharma has operations in Shenzhen, Jiangxi and Jilin. In the last 12 months, AMDL has traded between $2.20 and $5.58. In mid-session, it was priced at $3.31, down 5 cents.
ChinaBio Today is a regular contributor to BioHealth Investor
_______________
Thursday’s Top Biotech & Medical Stocks
by H.S. Ayoub
BioHealth Investor
Biotechnology
3SBIO INC [SSRX] +23.19%
REXAHN PHARMACEUTICL [RXHN.OB] +20.87%
CURAGEN CORP [CRGN] +15.38%
VIACELL, INC. [VIAC] +10.53%
EXACT SCIENCES COR [EXAS] +7.32%
Diagnostic Substances
[IMRX] +11.49%
ROSETTA GENOMICS LTD [ROSG] +4.84%
LEXICON PHARMACEUTCL [LXRX] +2.18%
INFINITY PHARMACEUTI [INFI] +1.98%
GENE LOGIC INC [GLGC] +1.63%
Drug Delivery
QUIGLEY CORP THE [QGLY] +8.28%
INSITE VISION INC [ISV] +4.96%
EMISPHERE TECH [EMIS] +3.30%
COLUMBIA LABS INC [CBRX] +3.20%
BENTLEY PHARMACEUTIC [BNT] +3.17%
Drug Manufacturers
ACUSPHERE INC [ACUS] +4.90%
PROVECTUS PHARMA [PVCT.OB] +4.84%
NEXMED INC [NEXM] +4.76%
MINRAD INTL INC [BUF] +3.25%
SIMCERE PHARMA ADS [SCR] +4.69%
Drug Related Products
CHINA SHENGHUO PHARM [KUN] +7.04%
TIENS BIOTECH GR USA [TBV] +4.92%
ZILA INC [ZILA] +4.55%
PACIFICHEALTH LABS [PHLI.OB] +2.15%
NATROL INC [NTOL] +1.61%
Generic Drugs
HI-TECH PHARMACAL [HITK] +1.72%
PHARMACUTICAL CO [PRX] +0.97%
CARACO PHARMA LABS [CPD] +0.57%
ISOLAGEN INC [ILE] +0.43%
BARR PHARMA INC [BRL] +0.21%
Medical Appliances & Equipment
VISION SCIENCES IN [VSCI] +8.24%
SYNOVIS LIFE TECH [SYNO] +7.13%
RESTORE MEDICAL INC [REST] +5.63%
CAMBRIDGE HEART INC [CAMH.OB] +4.17%
LANGER INC [GAIT] +4.12%
Medical Instruments & Supplies
VICOR TECHNOLOGIES [VCRT.OB] +19.81%
BIOSPHERE MEDICAL [BSMD] +16.29%
ROCHESTER MEDICAL [ROCM] +11.65%
CARDIOTECH INTL [CTE] +5.69%
OPHTHALMIC IMAGING SYS INC [OISI.OB] +3.70%
Medical Laboratories & Research
AETERNA ZENTARIS [AEZS] +4.47%
SPHERIX INC [SPEX] +2.42%
PSYCHEMEDICS NEW [PMD] +0.48%
BIO-REFERENCE LAB [BRLI] +0.43%
NATL DENTEX CP [NADX] +0.38%
- Wednesday’s Top Biotech & Medical Stocks
- Tuesday’s Top Biotech & Medical Stocks
____________________
Cancer Immunotherapy: Is the Hype Over and the Hope Beginning?
by Michael Shulman
BiotechBlitz
The simplistic and lazy cancer vaccines are immunotherapy: treatments that stimulate a patient’s immune system to fight cancer.
A decade or more ago, in a capital market far far away, cancer immunotherapies and treatments, and the companies that researched them were white hot. Due to the incredible time it takes to develop these therapies and the lack of clear regulatory guidance and pathways at the FDA, they have been stuck in trials — and, understandably, investors have run for cover.
But now, they may be on the rebound — for patients and for investors.
What is cancer immunotherapy?
I prefer a very narrow definition when talking about investments: new drugs designed to turn on the patient’s immune system to fight cancer on it’s own.
Wikipedia has a good working definition that also includes some broader approaches beyond my own definition.
When I talk about cancer immunotherapy (and when Wall Street talks about immunotherapy companies) it is the treatment, stimulation and management of a patient’s own immune system to fight cancer in many forms. Treatments are being developed to either prevent the onset of cancer, almost like a traditional vaccine or immunization, or to stimulate a patient’s immune system after the onset of the disease typically by injecting therapeutic antibodies.
Different kinds of cancer tumors have cells that have unusual type of antigens (go to Wikipedia for this one also) and these are often the targets of immunotherapies — especially antigens that appear on the surface of cancer cells and are relatively easy to get to.
Research scientists also look for something called “cell surface receptors.” These do not occur with any frequency in a healthy patient and are an integral part of the duplication process of cancer cells, and if an immune system can stop these receptors, a tumor, theoretically, could stop growing.
Who plays in this arena? The most infamous company is Dendreon (DNDN) and its prostate cancer treatment Provenge. The success (at a panel) and failure (with the FDA staff) of this drug in the approval process highlights the problems facing developers of these treatments. The problems:
What to treat? When these companies got started, “tumor shrinkage” or the stopping of tumor growth was all the rage. Now, they are being asked to extend life, a much more logical target but this changes things. Dendreon’s trials of Provenge failed to stop tumor progress but one small one seemed to show a survival benefit.Who is the regulator? Most cancer drugs are regulated by a group at the FDA known to some of us — the wittier ones — as statistical fascists. The panels convened by this group to review new treatments are dominated by practicing oncologists who see two weeks more survival as a relevant fact. It is not.
Some of the immunotherapy companies are regulated by a different group at FDA and they are far more sensitive to the issues facing brand new technology. This group stacked the panel looking at Provenge with seven immunologists — and lost the battle with the statistical fascists within the agency, and the drug was rejected. It was the first cancer treatment approved by a panel and rejected by staff in living memory. This mess — and it is a mess! — makes handicapping the potential success of a treatment in trial and the approval process very difficult.
How to measure progress? If life extension is what counts, trials need to be much longer than a trial to measure tumor progress — the new trial for Provenge is three years long — and trials need to be managed very well with most patients at the same stage of the disease when entering the trial.
Most start up biotechs lack the management ability to keep their bathroom stocked with toilet paper and are very poor at managing trials the way the FDA wants them managed. The executive teams at these companies are also populated with arrogant scientists not willing to listen or work with public servants. I kid you not. So many trials are still underway that are aiming at something other than life extension.
Manufacturing: Many of these treatments require processing of an individual’s patient’s blood — some involving the taking of tumor tissue samples — and this requires a manufacturing facility that requires FDA approval and a whole new FDA set of regulations. A great book is “Inside the FDA” by Fran Hawthorne, which will give you a good look at how tortured this process can be.
Does it work? Traditional high profile oncologists — used to poisoning and burning patients or giving them cocktails of drugs they put together outside FDA labels — want more data.
I don’t. Provenge clearly works on some sub-group of advanced prostate cancer patients, and these people are going to die anyway. Other treatments have failed, notably a treatment from Antigenics (AGEN). Let us hope the arrogant doctors who manage these companies and the arrogant doctors on the FDA panels abandon Francis Bacon, at his worst, and let one through. And then another, and another….
What does this mean for investors? Are there immunotherapy companies worth looking at? Maybe, maybe not.
Dendreon (DNDN): Avoid this dog. Management is screwing up the trial process again and the new trial will be interrupted to present interim results to get an expedited FDA approval at the end of 2008. The betting money is the trial will fail to show life extension because they enrolled the easier-to-find patients in the trial first – the sickest patients. A dumb move.
Cell Genesys (CEGE): They are also working in an advanced prostate cancer treatment, GVAX, and their trials are constructed to show life extension and also in conjunction with other known treatments, so if the therapy works, they may have a fighting chance to get an approval.
Antigenics (AGEN): Probably a dead company, their drug did not work, they have burned through oodles of investor cash, stay away.
Oxford Biomedica PLC (OXB: LSE, London Stock Exchange): They just concluded a huge deal with the Sanofi-aventis (SNY), potentially worth more than half a billion dollars, as SNY tries to play catch up in the $50-billion-dollar-per-annum cancer treatment market.
Big pharma: The dinosaurs working in this area are Sanofi-aventis, GlaxoSmthKline (GSK) and German company Merck Kga. Stay away, dinosaurs are just that, dinosaurs.
Bottom line: If investors continue to support these companies — and just one drug works and gets an approval — all hell will break loose to the upside for there is a great need for a next-generation approach to cancer treatment.
Biotech Blitz is a regular contributor to BioHealth Investor
______________
Wednesday’s Top Biotech & Medical Stocks
by H.S. Ayoub
BioHealth Investor
Biotechnology
INNOVIVE PHARMACEUTL [IVPH.OB] +21.62%
RENOVIS INC [RNVS] +20.48%
PROTALIX BIOTHERAPEU [PLX] +8.58%
ADVENTRX PHARMACTL [ANX] +8.41%
XENOPORT [XNPT] +8.22%
Diagnostic Substances
INTERLEUKIN GENETICS [ILI] +8.11%
ASPENBIO PHARMA INC [APPY] +5.66%
QUIDEL CP [QDEL] +4.75%
IMMUNOMEDICS INC [IMMU] +4.39%
IMMUCOR INC [BLUD] +3.75%
Drug Delivery
ACURA PHARMACEUTICAL [ACUR.OB] +14.09%
MATRIXX INITIATVS [MTXX] +3.57%
EMISPHERE TECH [EMIS] +3.41%
ARADIGM CORP [ARDM.OB] +2.96%
NOVEN PHARMACEUTIC [NOVN] +2.30%
Drug Manufacturers
WUXI PHARMATECH ADS [WX] +9.64%
DYNAVAX TECHNOLOGIES [DVAX] +8.60%
PROVECTUS PHARMA [PVCT.OB] +7.83%
PRANA BIO LTD ADS S1 [PRAN] +7.30%
SOMAXON PHARMACEUTIC [SOMX] +6.45%
Drug Related Products
USANA HEALTH SCIEN [USNA] +7.47%
TIENS BIOTECH GR USA [TBV] +6.64%
MANNATECH INC [MTEX] +4.61%
NATURAL ALTERNATIV [NAII] +2.19%
NATROL INC [NTOL] +1.64%
Generic Drugs
HI-TECH PHARMACAL [HITK] +2.19%
BARR PHARMA INC [BRL] +1.90%
WATSON PHARMACEUTCLS [WPI] +1.56%
Medical Appliances & Equipment
MEDICALCV INC [MCVI.OB] +13.20%
LAKELAND INDS INC [LAKE] +7.78%
HANSEN MEDICAL, INC. [HNSN] +5.37%
VARIAN MED SYS INC [VAR] +5.13%
[MASI] +4.70%
Medical Instruments & Supplies
BIOMIMETIC THERAPEUT [BMTI] +8.46%
ORTHOVITA INC [VITA] +6.51%
MEMRY CORPORATION [MRY] +5.63%
MINDRAY MEDICAL INTL [MR] +5.01%
OCULUS INNOVATIVE SC [OCLS] +4.85%
Medical Laboratories & Research
MEDTOX SCIENTFIC INC [MTOX] +4.14%
NEOGENOMICS INC [NGNM.OB] +4.00%
NATL DENTEX CP [NADX] +2.70%
ERESEARCHTECHNOLOG [ERES] +2.54%
PHARM PROD DEV [PPDI] +1.84%
- Tuesday’s Top Biotech & Medical Stocks
- Monday’s Top Biotech & Medical Stocks
____________________
Tuesday’s Top Biotech & Medical Stocks
by H.S. Ayoub
BioHealth Investor
Biotechnology
SANGAMO BIOSCIENCE [SGMO] +12.12%
KOSAN BIOSCIENCES [KOSN] +10.17%
ANIKA THERAPEUTICS [ANIK] +9.22%
BIONOVO INC [BNVI] +8.38%
ALTUS PHARMACEUTICAL [ALTU] +7.95%
Diagnostic Substances
HUMAN GENOME SCI [HGSI] +7.47%
ROSETTA GENOMICS LTD [ROSG] +5.66%
EPICEPT CORPORATION [EPCT] +5.14%
STARMED GROUP NEW [SMED.OB] +4.76%
ABAXIS INC [ABAX] +4.55%
Drug Delivery
ACURA PHARMACEUTICAL [ACUR.OB] +15.50%
NEKTAR THERAPEUTIC [NKTR] +5.74%
ARADIGM CORP [ARDM.OB] +5.47%
ALKERMES INC [ALKS] +4.30%
PETMED EXPRESS INC [PETS] +4.27%
Drug Manufacturers
MILLENNIUM PHARM [MLNM] +9.01%
TELIK INC [TELK] +7.29%
MINRAD INTL INC [BUF] +6.52%
ALEXZA PHARMACEUTICA [ALXA] +6.37%
PAIN THERAPEUTICS [PTIE] +6.05%
Drug Related Products
PRESTIGE BRAND HLGS [PBH] +7.72%
N B T Y INC [NTY] +5.14%
SALIX PHARM DEL [SLXP] +3.86%
AUXILIUM PHARMACEUT [AUXL] +3.15%
IMAGENETIX INC [IAGX.OB] +2.97%
Generic Drugs
PHARMACUTICAL CO [PRX] +12.62%
CATALYST PHARMACEUTI [CPRX] +6.21%
CARACO PHARMA LABS [CPD] +4.59%
HI-TECH PHARMACAL [HITK] +2.06%
BARR PHARMA INC [BRL] +2.00%
Medical Appliances & Equipment
MEDICALCV INC [MCVI.OB] +8.70%
REGENERATION TECH [RTIX] +7.63%
DEL GLOBAL TECH CORP [DGTC.OB] +7.41%
INTUITIVE SURG INC [ISRG] +5.91%
CONMED CP [CNMD] +5.67%
Medical Instruments & Supplies
BIOMERICA INC [BMRA.OB] +11.36%
CANTEL MEDICAL CORP [CMN] +9.33%
CRYOCOR, INC. [CRYO] +8.13%
AMDL, INC [ADL] +7.41%
ABIOMED INC [ABMD] +6.80%
Medical Laboratories & Research
ENZO BIOCHEM INC [ENZ] +7.33%
GENOMIC HEALTH, INC. [GHDX] +5.56%
ARRAY BIOPHARMA IN [ARRY] +3.45%
ALLIANCE IMAGING INC [AIQ] +3.17%
ERESEARCHTECHNOLOG [ERES] +3.07%
- Monday’s Top Biotech & Medical Stocks
- Friday’s Top Biotech & Medical Stocks
____________________
RNA Interference: NOT Better Late Than Never
by Michael Shulman
Biotech Blitz
RNA interference is arguably the hottest area of raw biotech research today.
And, up front, I don’t like it as a place for investors to put their money for two reasons — it’s too early, and it is too late.
It is far too early to see if this technology and approach for treating disease will pay off in the form of approved drugs and treatments.
It is too late because many of the stocks in this segment have been bid up due to M&A and partnership activity between the big pharma dinosaurs that are desperate for new approaches and the little itty bitty start ups a decade or more away from an approval drug.
And, like most investors, I don’t like it because I missed it.
What is RNA interference?
It is the use of RNA regulation of gene expression to inhibit the genetic direction given to disease — simply put, the use of RNA to mess up gene expression in disease. Check out the complete definition at Wikpedia if you are helping your children with their homework or if you want to pose as a scientist at a cocktail party .
There is an even more boring, ongoing discussion of the science at RNAi News. And if that gets you going, there is also a Genome News, but I will save that dor a rainy day. Last year, Craig C. Mello and Andrew Fire won the Nobel Prize for their work in RNA interference in roundworms. Too bad you cannot swallow these roundworms to cure what ails you.
Why am I such a cynic? Because RNAi is elegant but incredibly hard to manage and build into real drugs. The single biggest task is to get enough engineered RNA into a human cell — enough to treat the target disease. The problem is RNA is inherently volatile and unstable, so there is a great deal of work required on drug delivery and packaging before any of this becomes real. The first targets will be where drug delivery is easiest: A shot (literally) in the eye, inhaled treatments in the lungs and so on.
Stay with me folks! This is a blog about money, not RNAi pathways or molecules.
IS there still money to be made among the RNAi intereference stocks? I spent a good deal of time on this one, as late as this entry might be, and I am still uncomfortable. I admit a bias against investing based on the hope of M&A activity – but, well, it’s your dough.
And let me say, though, that RNA interference or something akin to it — something that modifies or suppresses the genetic sequences of disease — is arguably a holy grail in medical treatments, for it goes after the disease and the disease alone — at least we hope so — and leaves the rest of the body alone — again, we hope.
Alynlam (ALN): This used to be a true dog — it has now licensed more than $300 million in core technology to Roche and that company also got a 5% stake. A dog no more, and far too expensive to buy. Alynlam is also working with heavyweight device maker Medtronic.
Arrowhead Research (ARWR):This outfit invests in early stage research, including RNAi and then if anything it has comes close to success ARWR will partner it off or bring it to market.
CyTrx (CYTR): This company manages press releases and the growth spurts in its stock better than its labs and, cleverly enough, announced a new subsidiary to do RNAi-only research earlier in the year. Too much hype, not enough hope, stay away.
ISIS (ISIS): This company was in the news in the past few days as it cut a major deal to work collaboratively with Alnylam to form a company called Regulus to do research in microRNA, a derivative technology. Why? To eventually take this new outfit public because they are tired of losing money on RNAi research without a payoff. I will write about Regulus when it comes to market.
Merck (MRK) — through Sirna (formerly RNAI): Merck bought Sirna for $1.1 billion late last year to get into this game and Sirna was the only company with a drug in late-stage testing. The drug is for age related macular degeneration. It was this purchase that set off the frenzy in RNAi stocks. I think MRK is almost a short, let alone an investment, and I would stay away from Merck at all costs.
Rosetta Genomics (ROSG): This company is also specializing in microRNA and is the closest to a possible investment for me because it
a) is benefitting from the hundreds of milliosn spent by others on research, and
b) it has not done as well as others since its recent IPO so the stock is not ridiculously priced. If you look at the little things like revenues and profits ROSG is over priced, but compared to other RNA stocks that have burned through serious dough, it is in better shape — sort of.
Yes, I missed the run. But I also owned Dendreon (DNDN) at chump change prices, saw it go past $20 and got out. So I do get it right more than occasionally – and if you are going to go speculative, take a look at immunotherapy, next up here.
RELATED READING:
- RNAi: Next Phase or Next Fad?
- Micro RNAs: The Last Frontier of Medicine?
- RNAi developments by Alnylam, CytRx Highlight Tuesday’s Biotech News
- Merck Looking To Become RNAi Technology Leader
Biotech Blitz is a regular contributor to BioHealth Investor
______________
Monday’s Top Biotech & Medical Stocks
by H.S. Ayoub
BioHealth Investor
Biotechnology
GENTA INC [GNTA] +8.59%
POLYDEX PHARM LTD [POLXF] +6.42%
IMMTECH PHARM INC [IMM] +5.82%
LIFECELL CP [LIFC] +4.97%
ALNYLAM PHARMACEUT [ALNY] +4.43%
Diagnostic Substances
ROSETTA GENOMICS LTD [ROSG] +9.38%
SYNTA PHARMACEUTICAL [SNTA] +4.70%
SONUS PHARM INC [SNUS] +4.69%
SCOLR PHARMA INC [DDD] +3.57%
AVALON PHARMACEUTIC [AVRX] +3.27%
Drug Delivery
ACURA PHARMACEUTICAL [ACUR.OB] +8.40%
COLUMBIA LABS INC [CBRX] +1.28%
DELCATH SYSTEMS INC [DCTH] +1.00%
K V PHARMA CL A [KV-A] +0.14%
Drug Manufacturers
PRANA BIO LTD ADS S1 [PRAN] +7.76%
SOMAXON PHARMACEUTIC [SOMX] +4.14%
OSCIENT PHARMACEUT [OSCI] +3.79%
NEUROLOGIX INC [NRGX.OB] +2.36%
SIMCERE PHARMA ADS [SCR] +1.66%
Drug Related Products
NATROL INC [NTOL] +6.07%
MEDICAL NUTRITN USA [MDNU] +2.35%
LABOPHARM INC. [DDSS] +1.81%
PACIFICHEALTH LABS [PHLI.OB] +0.53%
NATURAL ALTERNATIV [NAII] +0.50%
Generic Drugs
LOTUS PHARMACEUTICAL [LTUS.OB] +7.14%
CATALYST PHARMACEUTI [CPRX] +4.44%
ISOLAGEN INC [ILE] +2.61%
MYLAN LABS INC [MYL] +0.59%
Medical Appliances & Equipment
SPECTRASCIENCE NEW [SCIE.OB] +14.29%
EMERGENT GROUP INC [EMGP.OB] +13.11%
SONTRA MEDICAL CORP [SONT.OB] +7.95%
FONAR CORP [FONR] +3.44%
REFLECT SCIENTIFIC [RSCF.OB] +2.86%
Medical Instruments & Supplies
OCULUS INNOVATIVE SC [OCLS] +38.45%
CAS MEDICAL SYS INC [CASM] +5.93%
INSULET CORPORATION [PODD] +4.60%
IMMUNOCELLULAR THERA [IMUC.OB] +4.55%
YOUNG INNOVATIONS [YDNT] +3.49%
Medical Laboratories & Research
MEDTOX SCIENTFIC INC [MTOX] +1.85%
ENZO BIOCHEM INC [ENZ] +1.44%
ALLIANCE IMAGING INC [AIQ] +1.38%
PHARM PROD DEV [PPDI] +0.66%
BIO-REFERENCE LAB [BRLI] +0.09%
- Friday’s Top Biotech & Medical Stocks
- Thursday’s Top Biotech & Medical Stocks
____________________
OpGen Raises $23.6 Million for DNA Analysis Technology
by Sara Calabro
Med Tech Sentinel
OpGen, a Madison, WI-based company whose technology analyzes DNA extracted from microbial cells, has raised $23.6 million in a Series A equity financing. The financing — led by CHL Medical Partners, Highland Capital Partners and Versant
Ventures, with previous investor Mason Wells also participating — will be used to develop diagnostic systems for the clinical microbiology market.
“Currently, clinical microbiology laboratories depend on isolating and growing microorganisms from clinical samples,” said CHL Medical Partners’ Ron Lennox, who was named chairman of OpGen’s board in conjunction with the financing. “This is a lengthy process and provides only a simple taxonomic identification. The results are rarely timely enough to influence choice of therapy and can lead to excessive use of expensive broad-spectrum antibiotics. OpGen’s new system will provide data capable of identifying bacteria down to the strain level, within a single shift.”
OpGen’s Optical Mapping system is already being used by organizations worldwide for comparative genomic analysis of a range of organisms of importance to human health, including tracing the origins of food-poisoning cases such as the recent outbreak linked to contaminated spinach. The system can be used to obtain detailed genetic information with no requirement for prior sequence data, PCR, cloning, or probes.
Applications for the new instrumentation systems include clinical microbial analysis, forensic microbiology and the development of novel molecular diagnostic products.
“There is a huge unmet need for systems to rapidly and accurately diagnose clinical infections and to control nosocomial infections,” said Corey Mulloy, from Highland Capital Partners.
Med Tech Sentinel is a regular contributor to BioHealth Investor
________________
Friday’s Top Biotech & Medical Stocks
by H.S. Ayoub
BioHealth Investor
Biotechnology
NORTHFIELD LABS IN [NFLD] +17.30%
EPIX PHARMACEUTICALS [EPIX] +10.28%
GENTA INC [GNTA] +9.40%
POLYMEDIX INC [PYMX.OB] +8.57%
SANGAMO BIOSCIENCE [SGMO] +8.39%
Diagnostic Substances
STARMED GROUP NEW [SMED.OB] +55.64%
RESPONSE GENETICS, I [RGDX] +18.68%
TORREYPINES THERAPEU [TPTX] +7.31%
SYNTA PHARMACEUTICAL [SNTA] +5.82%
ROSETTA GENOMICS LTD [ROSG] +5.02%
Drug Delivery
INSITE VISION INC [ISV] +8.77%
ACURA PHARMACEUTICAL [ACUR.OB] +6.25%
MATRIXX INITIATVS [MTXX] +5.78%
PETMED EXPRESS INC [PETS] +3.59%
COLUMBIA LABS INC [CBRX] +2.17%
Drug Manufacturers
DUSA PHARM INC [DUSA] +13.90%
DEPOMED INC [DEPO] +11.44%
NEUROGEN CP [NRGN] +10.86%
NITROMED, INC. [NTMD] +10.81%
AP PHARMA INC [APPA] +8.29%
Drug Related Products
MEDICAL NUTRITN USA [MDNU] +3.91%
TIENS BIOTECH GR USA [TBV] +2.10%
N B T Y INC [NTY] +1.20%
AUXILIUM PHARMACEUT [AUXL] +0.99%
PRESTIGE BRAND HLGS [PBH] +0.95%
Generic Drugs
LOTUS PHARMACEUTICAL [LTUS.OB] +16.67%
HI-TECH PHARMACAL [HITK] +4.08%
CATALYST PHARMACEUTI [CPRX] +2.09%
BARR PHARMA INC [BRL] +0.72%
CARACO PHARMA LABS [CPD] +0.45%
Medical Appliances & Equipment
NORTHSTAR NEUROSCI [NSTR] +8.22%
SONIC INNOVATIONS [SNCI] +2.97%
PHOTOMEDEX INC [PHMD] +2.94%
DYNATRONICS CP [DYNT] +2.88%
ATS MEDICAL INC [ATSI] +2.73%
Medical Instruments & Supplies
MEMRY CORPORATION [MRY] +7.52%
CHINA MEDICAL TECH [CMED] +6.90%
EP MEDSYSTEMS INC [EPMD] +6.90%
INOVIO BIOMED CORP [INO] +6.21%
ALPHATEC HOLDINGS [ATEC] +5.98%
Medical Laboratories & Research
NEOGENOMICS INC [NGNM.OB] +4.92%
GENOMIC HEALTH, INC. [GHDX] +2.13%
ARRAY BIOPHARMA IN [ARRY] +1.67%
RADNET INC [RDNT] +1.16%
PSYCHEMEDICS NEW [PMD] +0.89%
- Thursday’s Top Biotech & Medical Stocks
- Wednesday’s Top Biotech & Medical Stocks
____________________
Thursday’s Top Biotech & Medical Stocks
by H.S. Ayoub
BioHealth Investor
Biotechnology
GENTA INC [GNTA] +15.84%
CORCEPT THERAPEUTICS [CORT] +15.32%
ZIOPHARM ONCOLOGY IN [ZIOP] +6.71%
VIA PHARMACEUTICALS [VIAP] +5.88%
NORTHWEST BIOTH NEW [NWBO.OB] +4.44%
Diagnostic Substances
EPICEPT CORPORATION [EPCT] +19.63%
RESPONSE GENETICS, I [RGDX] +11.44%
REMOTEMDX INC [RMDX.OB] +7.93%
INTERLEUKIN GENETICS [ILI] +7.50%
SONUS PHARM INC [SNUS] +7.47%
Drug Delivery
ACURA PHARMACEUTICAL [ACUR.OB] +7.69%
GENEREX BIOTECH CORP [GNBT] +7.28%
INSITE VISION INC [ISV] +5.56%
NOVEN PHARMACEUTIC [NOVN] +3.16%
BIOVAIL CORP [BVF] +2.33%
Drug Manufacturers
PROTALEX INC [PRTX.OB] +14.17%
ACUSPHERE INC [ACUS] +6.11%
WUXI PHARMATECH ADS [wx] +4.93%
BIODEL INC. [BIOD] +4.28%
ISIS PHARM INC [ISIS] +4.23%
Drug Related Products
CHINA SHENGHUO PHARM [KUN] +2.49%
NUTRACEUTICAL INTL [NUTR] +1.52%
NATROL INC [NTOL] +1.38%
MEDICAL NUTRITN USA [MDNU] +1.24%
N B T Y INC [NTY] +0.83%
Generic Drugs
WATSON PHARMACEUTCLS [WPI] +2.75%
PHARMACUTICAL CO [PRX] +1.86%
ISOLAGEN INC [ILE] +0.88%
HI-TECH PHARMACAL [HITK] +0.37%
HELICOS BIOSCIENCES [HLCS] +0.21%
Medical Appliances & Equipment
LANGER INC [GAIT] +8.06%
ARRHYTHMIA RES TECH [HRT] +6.79%
DIGIRAD CORPORATION [DRAD] +6.73%
CAMBRIDGE HEART INC [CAMH.OB] +6.62%
EMERGENT GROUP INC [EMGP.OB] +6.06%
Medical Instruments & Supplies
ARRAY BIOPHARMA IN [ARRY] +3.55%
ERESEARCHTECHNOLOG [ERES] +2.74%
BIO-REFERENCE LAB [BRLI] +2.65%
ENZO BIOCHEM INC [ENZ] +1.87%
NATL DENTEX CP [NADX] +1.71%
Medical Laboratories & Research
ANGEION CORP [ANGN] +15.32%
ISORAY INC [ISR] +7.39%
NUVASIVE, INC. [NUVA] +5.29%
BIOMERICA INC [BMRA.OB] +5.07%
ARISTOTLE CP [ARTL] +4.42%
- Wednesday’s Top Biotech & Medical Stocks
- Tuesday’s Top Biotech & Medical Stocks
____________________